Phase I/II Study of Carboplatin and Pralatrexate in Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

Trial Profile

Phase I/II Study of Carboplatin and Pralatrexate in Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Carboplatin (Primary) ; Pralatrexate (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Nov 2016 Results (n=50) published in the Cancer.
    • 15 Jul 2016 Results published in the Cancer.
    • 25 Feb 2015 Planned End Date changed from 1 Aug 2014 to 1 Jan 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top